Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Baxter
Moodys
Mallinckrodt
Express Scripts

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR TOPAMAX


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Topamax

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006205 ↗ Alcohol Dependency Study: Combining Medication Treatment for Alcoholism Unknown status National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2005-03-01 The purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. This 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy.
NCT00006205 ↗ Alcohol Dependency Study: Combining Medication Treatment for Alcoholism Unknown status Bankole Johnson Phase 2 2005-03-01 The purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. This 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy.
NCT00167245 ↗ Topiramate for Alcohol and Cocaine Dependence Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2004-09-01 The primary purpose of this study is to test the effectiveness of topiramate for the treatment of combined alcohol and cocaine dependence. Topiramate is approved for the treatment of seizures. It has not been proven to be effective for the treatment of alcohol or cocaine dependence.
NCT00167245 ↗ Topiramate for Alcohol and Cocaine Dependence Completed Kyle Kampman Phase 2 2004-09-01 The primary purpose of this study is to test the effectiveness of topiramate for the treatment of combined alcohol and cocaine dependence. Topiramate is approved for the treatment of seizures. It has not been proven to be effective for the treatment of alcohol or cocaine dependence.
NCT00203190 ↗ A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache Terminated Ortho-McNeil Neurologics, Inc. Phase 4 2004-09-01 Topiramate is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with seizures. The trade name for this drug is Topamax┬«. Topiramate has not been approved by the FDA for the treatment of cluster headache and is experimental for the purposes of this research study. If a subject participates in this study, he/she will increase his/her dose of topiramate rapidly in the first few weeks to try to stop the cluster attacks and then will continue on a maintenance dose of topiramate in order to determine if it can prevent attacks from occurring during that cluster period. We believe that this will lead not only to a faster but a more complete remission of the cluster period.
NCT00203190 ↗ A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache Terminated Thomas Jefferson University Phase 4 2004-09-01 Topiramate is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with seizures. The trade name for this drug is Topamax┬«. Topiramate has not been approved by the FDA for the treatment of cluster headache and is experimental for the purposes of this research study. If a subject participates in this study, he/she will increase his/her dose of topiramate rapidly in the first few weeks to try to stop the cluster attacks and then will continue on a maintenance dose of topiramate in order to determine if it can prevent attacks from occurring during that cluster period. We believe that this will lead not only to a faster but a more complete remission of the cluster period.
NCT00203463 ↗ Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD) Completed Ortho-McNeil Janssen Scientific Affairs, LLC Phase 4 2001-07-01 To study the potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Topamax

Condition Name

Condition Name for Topamax
Intervention Trials
Healthy 12
Alcohol Dependence 11
Alcoholism 8
Epilepsy 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Topamax
Intervention Trials
Alcoholism 18
Migraine Disorders 12
Epilepsy 9
Disease 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Topamax

Trials by Country

Trials by Country for Topamax
Location Trials
United States 86
Canada 9
Germany 3
Thailand 3
Hong Kong 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Topamax
Location Trials
Pennsylvania 11
California 9
Virginia 9
Missouri 7
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Topamax

Clinical Trial Phase

Clinical Trial Phase for Topamax
Clinical Trial Phase Trials
Phase 4 23
Phase 3 8
Phase 2/Phase 3 4
[disabled in preview] 46
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Topamax
Clinical Trial Phase Trials
Completed 54
Terminated 11
Unknown status 8
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Topamax

Sponsor Name

Sponsor Name for Topamax
Sponsor Trials
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 10
National Institute on Drug Abuse (NIDA) 8
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 5
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Topamax
Sponsor Trials
Other 76
Industry 37
NIH 23
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Baxter
Harvard Business School
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.